Cancer Cell International (Dec 2021)

miR-378d suppresses malignant phenotype of ESCC cells through AKT signaling

  • Jie Peng,
  • Susu Shi,
  • Juan Yu,
  • Jianli Liu,
  • Haixiang Wei,
  • Haixia Song,
  • Shaoqiang Wang,
  • Zhejie Li,
  • Shujin He,
  • Lei Li,
  • Hongyan Zhang,
  • Zhizhen Yan,
  • Ran Zhao,
  • Yukun Liu,
  • Yanrong Liu,
  • Junjun Li,
  • Renya Zhang,
  • Wei Wang

DOI
https://doi.org/10.1186/s12935-021-02403-y
Journal volume & issue
Vol. 21, no. 1
pp. 1 – 13

Abstract

Read online

Abstract Background Post-resistance progress in paclitaxel (PTX) treatment remains a major challenge in tumor treatment. A high dose of PTX was used for cell lines to analyze the changes in molecular expression. The miR-378d was sharply reduced in surviving cells, but the role of miR-378d in Esophageal squamous cell carcinoma (ESCC) remained unclear. Methods We analyzed the relationship between miR-378d expression and the clinicopathological features of ESCC. We constructed miR-378d silent expression cell lines to study phenotypes and molecular mechanisms. Results The miR-378d expression was associated with good prognosis in patients with ESCC. miR-378d inhibition promoted chemo-resistance, monoclonal formation, EMT, migration, invasion, stemness, and metastasis of ESCC cells. miR-378d can target downregulated AKT1. Conclusions Therefore, miR-378d expression is a good prognostic factor of patients with ESCC and regulates the malignant phenotype of tumor cells through AKT.

Keywords